Silicon Labs Reports Third Quarter 2026 Results
Wireless IoT leader delivers
"We delivered strong third-quarter results, with revenue up 10% sequentially, underpinned by broad-based growth across many end applications and another record quarter for medical revenue as known customer ramps continued," said
Third Quarter Financial Highlights
- Revenue was
$251 million , up 22% year-over-year - Industrial & Commercial revenue was
$141 million , up 20% year-over-year Home & Life revenue was$110 million , up 24% year-over-year- Bookings imply a healthy demand environment, while distributor inventory declined further to a multi-year low and end customer inventory was near record lows during the quarter
- Medical revenue reached a new quarterly record, increasing 48% sequentially and more than 300% year-over-year
- GAAP diluted earnings per share was
$0.26 , compared with a loss of$0.30 in the year-ago quarter - Non-GAAP diluted earnings per share was
$1.05 , up 228% over the comparable period last year
Results on a GAAP basis:
- GAAP gross margin was 60.8%
- GAAP operating expenses were
$145 million - GAAP operating income was
$8 million - GAAP diluted earnings per share was
$0.26
Results on a non-GAAP basis, excluding the impact of stock compensation, amortization of acquired intangible assets, merger-related costs, and certain other items as set forth in the below GAAP to Non-GAAP reconciliation tables were as follows:
- Non-GAAP gross margin was 61.0%
- Non-GAAP operating expenses were
$113 million - Non-GAAP operating income was
$40 million - Non-GAAP diluted earnings per share was
$1.05
Due to the announced pending acquisition of
About
Forward-Looking Statements
This press release contains forward-looking statements regarding
Note to editors:
For more information: Silicon Labs Investor Relations, investor.relations@silabs.com
|
Condensed Consolidated Statements of Operations (In thousands, except per share data) (Unaudited) |
|||||||
|
|
|
|
|
||||
|
|
Three Months Ended |
|
Nine Months Ended |
||||
|
|
|
|
|
|
|
|
|
|
Revenues |
$ 250,892 |
|
$ 205,999 |
|
$ 692,581 |
|
$ 576,558 |
|
Cost of revenues |
98,314 |
|
86,980 |
|
272,331 |
|
251,653 |
|
Gross profit |
152,578 |
|
119,019 |
|
420,250 |
|
324,905 |
|
Operating expenses: |
|
|
|
|
|
|
|
|
Research and development |
93,174 |
|
87,685 |
|
276,784 |
|
263,725 |
|
Selling, general and administrative |
51,453 |
|
43,676 |
|
163,263 |
|
128,469 |
|
Operating expenses |
144,627 |
|
131,361 |
|
440,047 |
|
392,194 |
|
Operating income (loss) |
7,951 |
|
(12,342) |
|
(19,797) |
|
(67,289) |
|
Other income (expense): |
|
|
|
|
|
|
|
|
Interest income and other, net |
3,185 |
|
3,046 |
|
9,300 |
|
10,672 |
|
Interest expense |
(226) |
|
(226) |
|
(709) |
|
(761) |
|
Income (loss) before income taxes |
10,910 |
|
(9,522) |
|
(11,206) |
|
(57,378) |
|
Provision for income taxes |
2,059 |
|
414 |
|
6,432 |
|
4,845 |
|
Net income (loss) |
$ 8,851 |
|
$ (9,936) |
|
$ (17,638) |
|
$ (62,223) |
|
|
|
|
|
|
|
|
|
|
Earnings (loss) per share: |
|
|
|
|
|
|
|
|
Basic |
$ 0.27 |
|
$ (0.30) |
|
$ (0.53) |
|
$ (1.91) |
|
Diluted |
$ 0.26 |
|
$ (0.30) |
|
$ (0.53) |
|
$ (1.91) |
|
|
|
|
|
|
|
|
|
|
Weighted-average common shares outstanding: |
|
|
|
|
|
|
|
|
Basic |
33,376 |
|
32,835 |
|
33,182 |
|
32,656 |
|
Diluted |
33,752 |
|
32,835 |
|
33,182 |
|
32,656 |
Non-GAAP Financial Measurements
In addition to the GAAP results provided throughout this document,
The non-GAAP financial measurements do not replace the presentation of
|
Unaudited Reconciliation of GAAP to Non-GAAP Financial Measures (In thousands, except per share data) |
||||||||||||||
|
|
|
|
||||||||||||
|
|
|
Three Months Ended |
||||||||||||
|
Non-GAAP Income Statement Items |
|
GAAP Measure |
|
GAAP Percent of Revenue |
|
Stock Compensation Expense |
|
Intangible Amortization |
|
Merger- |
|
Non- Measure |
|
Non-GAAP Percent of Revenue |
|
Revenues |
|
$ 250,892 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross profit |
|
152,578 |
|
60.8 % |
|
$ 459 |
|
$ — |
|
$ — |
|
|
|
61.0 % |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development |
|
93,174 |
|
37.1 % |
|
11,996 |
|
2,295 |
|
3,623 |
|
75,260 |
|
30.0 % |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selling, general and administrative |
|
51,453 |
|
20.5 % |
|
10,594 |
|
— |
|
3,281 |
|
37,578 |
|
15.0 % |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating expenses |
|
144,627 |
|
57.6 % |
|
22,590 |
|
2,295 |
|
6,904 |
|
112,838 |
|
45.0 % |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating income |
|
7,951 |
|
3.2 % |
|
23,049 |
|
2,295 |
|
6,904 |
|
40,199 |
|
16.0 % |
|
|
|
Three Months Ended |
||||||||||
|
Non-GAAP Earnings Per Share |
|
GAAP Measure |
|
Stock Compensation Expense* |
|
Intangible Asset Amortization* |
|
Merger- |
|
Income Tax Adjustments** |
|
Non- GAAP Measure |
|
Net income (loss) |
|
$ 8,851 |
|
$ 23,049 |
|
$ 2,295 |
|
$ 6,904 |
|
$ (5,710) |
|
$ 35,389 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
Diluted shares outstanding |
|
33,752 |
|
|
|
33,752 |
||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted earnings per share |
|
$ 0.26 |
|
|
|
|
|
|
|
|
|
$ 1.05 |
|
* Represents pre-tax amounts |
|
** Represents the application of an 18% non-GAAP tax rate |
|
Condensed Consolidated Balance Sheets (In thousands, except per share data) (Unaudited) |
|||
|
|
|
|
|
|
|
|
|
|
|
Assets |
|
|
|
|
Current assets: |
|
|
|
|
Cash and cash equivalents |
$ 423,013 |
|
$ 364,222 |
|
Short-term investments |
16,828 |
|
79,400 |
|
Accounts receivable, net |
79,966 |
|
64,513 |
|
Inventories |
133,391 |
|
95,566 |
|
Prepaid expenses and other current assets |
71,421 |
|
70,316 |
|
Total current assets |
724,619 |
|
674,017 |
|
Property and equipment, net |
131,687 |
|
128,643 |
|
|
376,389 |
|
376,389 |
|
Other intangible assets, net |
16,246 |
|
23,130 |
|
Other assets, net |
87,213 |
|
67,138 |
|
Total assets |
$ 1,336,154 |
|
$ 1,269,317 |
|
Liabilities and Stockholders' Equity |
|
|
|
|
Current liabilities: |
|
|
|
|
Accounts payable |
$ 68,860 |
|
$ 50,717 |
|
Deferred revenue and returns liability |
9,804 |
|
5,359 |
|
Other current liabilities |
78,841 |
|
87,711 |
|
Total current liabilities |
157,505 |
|
143,787 |
|
Other non-current liabilities |
53,267 |
|
31,112 |
|
Total liabilities |
210,772 |
|
174,899 |
|
Commitments and contingencies |
|
|
|
|
Stockholders' equity: |
|
|
|
|
Preferred stock – |
— |
|
— |
|
Common stock – |
3 |
|
3 |
|
Additional paid-in capital |
206,203 |
|
157,402 |
|
Retained earnings |
919,176 |
|
936,814 |
|
Accumulated other comprehensive income |
— |
|
199 |
|
Total stockholders' equity |
1,125,382 |
|
1,094,418 |
|
Total liabilities and stockholders' equity |
$ 1,336,154 |
|
$ 1,269,317 |
|
Condensed Consolidated Statements of Cash Flows (In thousands) (Unaudited) |
|||
|
|
|
||
|
|
Nine Months Ended |
||
|
|
|
|
|
|
Operating Activities |
|
|
|
|
Net loss |
$ (17,638) |
|
$ (62,223) |
|
Adjustments to reconcile net loss to net cash provided by operating activities: |
|
|
|
|
Depreciation of property and equipment |
18,154 |
|
18,769 |
|
Amortization of other intangible assets |
6,884 |
|
11,074 |
|
Stock-based compensation expense |
69,754 |
|
59,645 |
|
Deferred income taxes |
2,164 |
|
2,026 |
|
Changes in operating assets and liabilities: |
|
|
|
|
Accounts receivable |
(15,453) |
|
(12,829) |
|
Inventories |
(37,828) |
|
23,316 |
|
Prepaid expenses and other assets |
(35,213) |
|
9,080 |
|
Accounts payable |
18,373 |
|
11,141 |
|
Other current liabilities and income taxes |
3,271 |
|
29,901 |
|
Deferred revenue and returns liability |
4,445 |
|
5,374 |
|
Other non-current liabilities |
20,285 |
|
(7,916) |
|
Net cash provided by operating activities |
37,198 |
|
87,358 |
|
|
|
|
|
|
Investing Activities |
|
|
|
|
Purchases of marketable securities |
— |
|
(34,790) |
|
Sales of marketable securities |
— |
|
15,332 |
|
Maturities of marketable securities |
62,309 |
|
22,598 |
|
Purchases of property and equipment |
(28,472) |
|
(19,942) |
|
Proceeds from capital-related government incentives |
8,705 |
|
— |
|
Purchase of other investment |
— |
|
(4,000) |
|
Net cash provided by (used in) investing activities |
42,542 |
|
(20,802) |
|
|
|
|
|
|
Financing Activities |
|
|
|
|
Payment of taxes withheld for vested stock awards |
(28,710) |
|
(14,907) |
|
Proceeds from the issuance of common stock |
7,761 |
|
8,147 |
|
Net cash used in financing activities |
(20,949) |
|
(6,760) |
|
|
|
|
|
|
Increase in cash and cash equivalents |
58,791 |
|
59,796 |
|
Cash and cash equivalents at beginning of period |
364,222 |
|
281,607 |
|
Cash and cash equivalents at end of period |
$ 423,013 |
|
$ 341,403 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/silicon-labs-reports-third-quarter-2026-results-302935539.html
SOURCE
